Showing results (171-180 of 244) with videos related to

Sort By:
Pageof 25
Cancers|June 2, 2021
Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up ConsultationMarion Nicolas, Beatriz Grandal, Emma Dubost, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2016
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trialMichail Ignatiadis, Brigitte Rack, Francoise Rothé, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 statusSylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, et al.
The Lancet. Oncology|December 28, 2020
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 studyAntoinette R Tan, Seock-Ah Im, André Mattar, et al.
Plos One|March 26, 2013
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinomaFabien Reyal, David Hajage, Alexia Savignoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast CancerWolfgang J Janni, Brigitte Rack, Leon W M M Terstappen, et al.
EJNMMI Research|December 14, 2019
Dual time point [18F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissuesPierre Lovinfosse, Caroline Rousseau, Jean-Yves Pierga, et al.
Molecular Oncology|January 13, 2015
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor typesRonald Lebofsky, Charles Decraene, Virginie Bernard, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
The New England Journal of Medicine|September 16, 2024
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerAditya Bardia, Xichun Hu, Rebecca Dent, et al.
Pageof 25